Results 81 to 90 of about 456,696 (362)

The epigenomics of sarcoma

open access: yesNature Reviews Cancer, 2020
Epigenetic regulation is critical to physiological control of development, cell fate, cell proliferation, genomic integrity, and fundamentally, transcriptional regulation. This epigenetic control occurs at multiple levels including through DNA methylation, histone modification, nucleosome remodeling, and modulation of the three-dimensional chromatin ...
Jamie S.E. Yu   +8 more
openaire   +4 more sources

Stochastic variation in the FOXM1 transcription program mediates replication stress tolerance

open access: yesMolecular Oncology, EarlyView.
Cellular heterogeneity is a major cause of drug resistance in cancer. Segeren et al. used single‐cell transcriptomics to investigate gene expression events that correlate with sensitivity to the DNA‐damaging drugs gemcitabine and prexasertib. They show that dampened expression of transcription factor FOXM1 and its target genes protected cells against ...
Hendrika A. Segeren   +4 more
wiley   +1 more source

The long non-coding RNA MYCNOS-01 regulates MYCN protein levels and affects growth of MYCN-amplified rhabdomyosarcoma and neuroblastoma cells

open access: yesBMC Cancer, 2018
Background MYCN is amplified in small cell lung cancers and several pediatric tumors, including alveolar rhabdomyosarcomas and neuroblastomas. MYCN protein is known to play a key oncogenic role in both alveolar rhabdomyosarcomas and neuroblastomas.
Eleanor M. O’Brien   +4 more
doaj   +1 more source

Ewing`S Sarcoma

open access: yesJournal of Education, Health and Sport, 2017
Budny Agnieszka, Litak Jakub, Kulesza Bartłomiej, Czyżewski Wojciech, Grochowski Cezary. Ewing`s Sarcoma. Journal of Education, Health and Sport. 2017;7(6):265-272. eISSN 2391-8306. DOI http://dx.doi.org/10.5281/zenodo.804631 http://ojs.ukw.edu.pl/index.php/johs/article/view/4534 The journal has had 7 points in Ministry of Science and ...
Cezary Grochowski   +4 more
openaire   +4 more sources

Targeting PRAME directly or via EZH2 inhibition overcomes retinoid resistance and represents a novel therapy for keratinocyte carcinoma

open access: yesMolecular Oncology, EarlyView.
The study evaluated the function and therapeutic implications of PRAME in basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). The findings demonstrate that PRAME impairs keratinocyte differentiation pathways. Furthermore, PRAME impairs anticancer response to retinoid compounds in BCC and SCC cells.
Brandon Ramchatesingh   +6 more
wiley   +1 more source

Myolipoma Affecting the Erector Spinae: A Case Report in a Child

open access: yesCase Reports in Medicine, 2009
Myolipoma is a rare, benign, lipomatous tumour which most commonly occurs in the retroperitoneum, pelvis, and abdomen. A 4-year-old boy presented with a painless enlarging mass in the left paraspinal region.
M. T. R. Parratt   +5 more
doaj   +1 more source

Definitive Radiotherapy in the Management of Non-Resectable or Residual Retroperitoneal Sarcomas: Institutional Cohort Analysis and Systematic Review

open access: yesCancer Control, 2021
Background: There is currently no consensus on optimal management of patients with primary or recurrent non-resectable/residual retroperitoneal sarcomas (RPS). The objective of this study was to document the outcomes of patients with primary or recurrent
Aleksandra Sobiborowicz   +3 more
doaj   +1 more source

Targeted antiangiogenic agents in combination with cytotoxic chemotherapy in preclinical and clinical studies in sarcoma. [PDF]

open access: yes, 2016
Sarcomas are a heterogeneous group of mesenchymal malignancies. In recent years, studies have demonstrated that inhibition of angiogenic pathways or disruption of established vasculature can attenuate the growth of sarcomas.
DuBois, Steven G   +2 more
core   +1 more source

Ewing sarcoma

open access: yesNature Reviews Disease Primers, 2018
Ewing sarcoma is the second most frequent bone tumour of childhood and adolescence that can also arise in soft tissue. Ewing sarcoma is a highly aggressive cancer, with a survival of 70-80% for patients with standard-risk and localized disease and ~30% for those with metastatic disease.
Grünewald, Thomas G. P.   +8 more
openaire   +4 more sources

TOMM20 as a driver of cancer aggressiveness via oxidative phosphorylation, maintenance of a reduced state, and resistance to apoptosis

open access: yesMolecular Oncology, EarlyView.
TOMM20 increases cancer aggressiveness by maintaining a reduced state with increased NADH and NADPH levels, oxidative phosphorylation (OXPHOS), and apoptosis resistance while reducing reactive oxygen species (ROS) levels. Conversely, CRISPR‐Cas9 knockdown of TOMM20 alters these cancer‐aggressive traits.
Ranakul Islam   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy